cytochrome P450 family 2 subfamily AB member 1, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP2AB1P profile across patient tissues and cancer cell-line models. CYP2AB1P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CYP2AB1P is differentially expressed in 10, with the highest sampling consensus in STAD. Additionally, CYP2AB1P RNA expression shows 7,455 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, STAD, and ACC as cancer lineages where CYP2AB1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2AB1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2AB1P survival associations across molecular data types. CYP2AB1P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2AB1P RNA expression–survival associations across cancer types. High CYP2AB1P expression shows unfavorable associations in KICH, KIRC, STAD, UCS and ACC, but favorable associations in COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CYP2AB1P RNA expression.
This table summarizes CYP2AB1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2AB1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2AB1P shows lower tumor expression in STAD, KIRC and ESCA and higher tumor expression in HNSC, LUSC and CHOL. The STAD box plot shows higher CYP2AB1P RNA expression in normal versus tumor tissue (log2 FC = −0.546, t-test p = .005).
This table shows molecular features associated with CYP2AB1P in patient tissues and cancer cell lines. In patient samples, CYP2AB1P shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
